Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3044)	7/19/2010 2:06:33 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ALXA is trying again to go over the resistance at the $3 level.<g> The stock is up 9.45% trading close to its intraday H and just above the $3 level bigcharts.marketwatch.com A week ago it announced that it has selected AZ-007 for the treatment of insomnia as the next product candidate to move forward into active development.<g> ALXA is planing its AZ-007 for patients with midnite insomnia by combining its Staccato system with zalepiom, which is a non-benzodiazepine hypnotic currently approved to treat insomnia, has a pharmacokinetic half-life of about one hour and is generally well tolerated. With AZ-007, they expect to obtain a rapid onset of action and avoid somnolence in the morning with the short-lived duration of action from the pharmacological half-life of zaleplon.<g> ALXA has small LTD. About $0.78 in chs/shr In spite of much higher loss in the 1stQ it is expected to end the Yr. wit a lower loss and to trim the loss a little more in 2011.<g> The ACTAY is $6.67 I will put a TT at $4 pending further developments.<g> bigcharts.marketwatch.com Bernard